Novavax, Inc. (NVAX) — closed signal from March 6, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 4, 2026.
Predicted vs. what happened
What happened
Reached 68% of the predicted growth at its peak, without hitting the target.
The thesis — published March 6, 2026
Novavax looks like a real turnaround: recent results surprised positively, the company reported short-term profits, and a new deal with Pfizer shifts more revenue toward royalties. The business situation and investor interest are both improving, so the next few months could be attractive if the company keeps delivering and partners follow through.
Primary drivers
- Positive earnings reset the idea that the company is recovering
- Pfizer deal moves revenue toward steady royalties
- More buyers are returning, showing renewed investor interest
- Valuation could rise if the company keeps executing well
How it played out
NVAX: target missed, but shares rose inside the window
Lyra published NVAX at $9.64 on March 6, 2026, with 30% expected growth over a short-term window. The thesis pointed to positive earnings, short-term profits, a Pfizer deal that could shift revenue toward royalties, returning buyers, and a valuation that could rise if execution held up.
Inside the window, the stock rose but did not reach the $12.53 target. It peaked at $11.61 on May 27, 2026, for a 20.4% gain, then ended the window at $10.19 on June 4, 2026. The thesis partially played out. It never got there.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.